Genmab A/S Stock Other OTC
Stocks
GNMSF
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 95.53B 14.84B 12.77B 11.76B 11.05B 20.75B 1,404B 20.99B 139B 54.14B 689B 55.69B 54.5B 2,379B | P/E Ratio 2026 * |
20.6x | P/E Ratio 2027 * | 14.3x |
|---|---|---|---|---|---|
| Enterprise Value | 115B 17.87B 15.37B 14.16B 13.31B 24.99B 1,690B 25.27B 167B 65.19B 830B 67.05B 65.62B 2,865B | EV / Sales 2026 * |
4.16x | EV / Sales 2027 * | 3.33x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -1.32% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 65 | 2020-03-25 |
| Director/Board Member | 75 | 2003-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 66 | 2016-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.32% | +1.72% | - | - | 15.19B | |
| -0.71% | -0.97% | +50.38% | +109.48% | 54.92B | |
| -1.22% | +2.25% | +43.78% | +38.45% | 44.31B | |
| -1.43% | +4.68% | -16.02% | -20.80% | 22.96B | |
| -1.99% | +1.43% | -3.25% | +377.36% | 21.12B | |
| -2.91% | -1.18% | +7.21% | -36.53% | 16.31B | |
| -1.70% | +0.70% | +25.27% | +172.77% | 13.32B | |
| +1.48% | +11.36% | +22.59% | - | 12.48B | |
| +4.10% | +7.02% | +104.41% | +226.33% | 11.21B | |
| +0.29% | +7.26% | +69.57% | +96.14% | 11.52B | |
| Average | -0.54% | +3.56% | +33.77% | +120.40% | 23.13B | |
| Weighted average by Cap. | -0.85% | +2.51% | +33.53% | +105.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.64B 4.29B 3.7B 3.4B 3.2B 6.01B 406B 6.07B 40.15B 15.67B 199B 16.12B 15.77B 689B | 32.41B 5.04B 4.33B 3.99B 3.75B 7.04B 476B 7.12B 47.07B 18.37B 234B 18.9B 18.49B 807B |
| Net income | 4.71B 732M 630M 580M 545M 1.02B 69.26B 1.04B 6.84B 2.67B 34B 2.75B 2.69B 117B | 7.02B 1.09B 938M 864M 812M 1.53B 103B 1.54B 10.19B 3.98B 50.64B 4.09B 4.01B 175B |
| Net Debt | 19.49B 3.03B 2.6B 2.4B 2.25B 4.23B 286B 4.28B 28.3B 11.05B 141B 11.36B 11.12B 485B | 12.47B 1.94B 1.67B 1.54B 1.44B 2.71B 183B 2.74B 18.11B 7.07B 89.97B 7.27B 7.11B 311B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
